期刊文献+

优化治疗慢性复发性丙型肝炎效果分析

下载PDF
导出
摘要 目的研究优化治疗慢性复发性丙型肝炎临床效果。方法选取2010年6月至2015年10月至我科治疗的慢性复发性丙肝患者62例,随机分成甲、乙两组,每组31例;甲组采用标准治疗延长疗程的方案、乙组采用标准治疗加大剂量的方案;以观察患者的持续病毒学应答(SVR)来比较治疗效果,并观察其6个月后的复发情况。结果甲组SVR应答率45.16%、复发率6.45%;乙组SVR应答率12.90%、复发率45.16%;两组比较,应答率、复发率均有显著性差异(P<0.01);治疗过程中出现的不良反应,两组比较差异无统计学意义(P>0.05)。结论采用标准治疗延长疗程方案,较加大剂量方案,在慢性复发性丙型肝炎的临床治疗上,可以实现更高的SVR应答率;减少复发和不良反应的发生。
作者 李有清
出处 《现代消化及介入诊疗》 2016年第2期230-231,共2页 Modern Interventional Diagnosis and Treatment in Gastroenterology
  • 相关文献

参考文献3

二级参考文献34

  • 1Meetings[J].World Journal of Gastroenterology,2010,16(1). 被引量:25
  • 2魏来.丙型肝炎研究进展[J].中国继续医学教育,2010,2(3):9-17. 被引量:10
  • 3Giada Sebastiani,Alfredo Alberti.Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy[J].World Journal of Gastroenterology,2006,12(23):3682-3694. 被引量:33
  • 4Husa P, Slesinger P, Stroblov: H, et al. Efficacy of pegylatedinterferon alpha-2a and ribavifin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics. Kiln Mikrobiol Infeke Lek,200,4:67-73.
  • 5Veldt B J, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon mono-therapy. Gut, 2004,53:1504 - 1508.
  • 6Swain MG, Lai MY, Shiman ML, et al. Durable sustained virological response after treatment with peginterferon alpha-2a (PEGASYS (R)) alone or in combination with ribavirin ( COPEGUS (R) ) : 5-year follow-up and the criteria of a cure. J Hepatol 2007,46:3A.
  • 7Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat, 2006,13:409-414.
  • 8Manns MP, McHutchison JG, Gordon SC, ct al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C : a randomised trial. Lancet,2001, 358:958-965.
  • 9Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with diffficuh-to-treat characteristics : randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology, 2008, 48 : 1033-1043.
  • 10Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with pegintefferon alfa-2a ( 40 KD )/ribavirin. J Hepatol, 200,43 : 425-433.

共引文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部